ArticleBioMed research international2021
Anti-influenza A Virus Effects and Mechanisms of Emodin and Its Analogs via Regulating PPAR
Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- NADThe Journal of general virology · 2026Review
- 2-Methoxystypandrone fromAntioxidants (Basel, Switzerland) · 2026Article
- Shen-Shuai-II-Recipe inhibits aerobic glycolysis through SIRT1 in 5/6 ablation/infarction renal failure model.Scientific reports · 2026Article
- Article
- Antiviral treatment for viral pneumonia: current drugs and natural compounds.Virology journal · 2025Review
- Investigation of the effect and mechanisms of moxa smoke in the treatment of Influenza A Virus (IAV) infection.PloS one · 2025Article
- Integrating multi-dimensional data to reveal the mechanisms and molecular targets of baikening granules for treatment of pediatric influenza.Frontiers in molecular biosciences · 2025Article
- Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.International journal of molecular sciences · 2023Article
- Quinones as Promising Compounds against Respiratory Viruses: A Review.Molecules (Basel, Switzerland) · 2023Review
- Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases.Cells · 2023Review
- PI3K/Akt/Nrf2 mediated cellular signaling and virus-host interactions: latest updates on the potential therapeutic management of SARS-CoV-2 infection.Frontiers in molecular biosciences · 2023Review
- Chronic exposure to low-level lipopolysaccharide dampens influenza-mediated inflammatory responseFrontiers in immunology · 2023Article
- Promising Role of Emodin as Therapeutics to Against Viral Infections.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The peroxisome proliferator-activated receptor (PPAR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.